Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Home on the range where the buffalo roam -- Ignore unavailable to you. Want to Upgrade?

To: D.B. Cooper who wrote (8229)	7/17/2002 9:27:43 AM
From: D.B. Cooper	Respond to of 13815

6:53AM Johnson & Johnson reports rise in blood disorders among Eprex users (JNJ) 50.10: Reuters reports that the number of kidney patients treated with anaemia drug who have developed a rare but serious blood disorder is continuing to rise. In a letter to European doctors, J&J said it was now aware of 141 reports of suspected pure red-blood cell aplasia (including one death) in patients treated with Eprex (this was reported in a Merrill Lynch note yesterday morning). Most of the adverse reactions have been in patients given skin injections. Amgen (AMGN), which markets Epogen for kidney dialysis patients, said on Monday that there had been only two reports of aplasia in patients taking Epogen.